Journal of Critical Care Highlights Promising Results of AdrenoMed's AdrenOSS-2 Trial

The Journal of Critical Care has published promising results from a subgroup analysis of AdrenoMed AG's Phase II AdrenOSS-2 trial. This study focuses on enibarcimab, a drug designed to address septic shock, using a biomarker-guided method targeting bio-ADM and DPP3 biomarkers.

The trial's results indicated that enibarcimab improved organ function and reduced 28-day mortality. Specifically, the mortality rate was 18% in the enibarcimab group compared to 26% among placebo patients. Enibarcimab showed a significant improvement in the SOFA score.

The results support future development, prompting a Phase IIb/III BOOST trial. AdrenoMed aims to further validate the efficacy of enibarcimab and advance it toward market authorization, offering hope for improved septic shock treatment.